| |  Online-Ressource |
|---|
| Verfasst von: | Pelegrin, Laura [VerfasserIn]  |
|---|
| | Jakob, Eva [VerfasserIn] |
|---|
| | Schmidt-Bacher, Annette [VerfasserIn] |
|---|
| | Schwenger, Vedat [VerfasserIn] |
|---|
| | Becker, Matthias [VerfasserIn] |
|---|
| | Max, Regina [VerfasserIn] |
|---|
| | Lorenz, Hanns-Martin [VerfasserIn] |
|---|
| | Mackensen, Friederike [VerfasserIn] |
|---|
| Titel: | Experiences with rituximab for the treatment of autoimmune diseases with ocular involvement |
|---|
| Verf.angabe: | Laura Pelegrin, Eva Jakob, Annette Schmidt-Bacher, Vedat Schwenger, Matthias Becker, Regina Max, Hans Martin Lorenz, and Friederike Mackensen |
|---|
| Jahr: | 2014 |
|---|
| Jahr des Originals: | 2013 |
|---|
| Umfang: | 7 S. |
|---|
| Fussnoten: | First Release: Nov 15, 2013 ; Gesehen am 03.11.2020 |
|---|
| Titel Quelle: | Enthalten in: The journal of rheumatology |
|---|
| Ort Quelle: | Toronto, Ont., 2001 |
|---|
| Jahr Quelle: | 2014 |
|---|
| Band/Heft Quelle: | 41(2014), 1, Seite 84-90 |
|---|
| ISSN Quelle: | 1499-2752 |
|---|
| Abstract: | Objective. To report the efficacy of rituximab (RTX) in the treatment of ocular or orbital inflammation accompanying autoimmune diseases refractory to previous standard immunosuppressive therapy. - Methods. We reviewed medical records of 9 consecutive patients with noninfectious ocular or orbital inflammation treated with RTX. - Results. Over a mean followup of 42 months, 7 patients were in clinical remission, 1 had partial response to treatment, and 1 did not respond. Best corrected visual acuity improved ≥ 1 line in 4 patients, was stable in another 4 patients, and worsened in 1. Concomitant immunosuppressive therapy was tapered in 6 cases. Systemic corticosteroids were tapered or kept below 7.5 mg a day in 5 patients 1 year after the first RTX cycle. - Conclusion. RTX therapy, in patients who are refractory to standard immunosuppressive therapy, was effective and showed a beneficial response to treatment including induction of clinical remission of inflammation in most patients. |
|---|
| DOI: | doi:10.3899/jrheum.130206 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.3899/jrheum.130206 |
|---|
| | Volltext: https://www.jrheum.org/content/41/1/84 |
|---|
| | DOI: https://doi.org/10.3899/jrheum.130206 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | CLINICAL REMISSION |
|---|
| | GRANULOMATOUS POLYANGIITIS |
|---|
| | OCULAR INFLAMMATION |
|---|
| | ORBITAL INFLAMMATION |
|---|
| | RITUXIMAB |
|---|
| K10plus-PPN: | 1737618397 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Experiences with rituximab for the treatment of autoimmune diseases with ocular involvement / Pelegrin, Laura [VerfasserIn]; 2014 (Online-Ressource)
